Grand River Aseptic Manufacturing Sponsoring Grand Rapids .1K to End Duchenne
Grand River Aseptic Manufacturing (GRAM), a leading parenteral contract manufacturing organization, is sponsoring the Grand Rapids .1K (GR.1K). Proceeds from the 100-meter race on Nov. 4 will be donated to Parent Project Muscular Dystrophy (PPMD), the largest U.S. nonprofit organization focused on ending Duchenne muscular dystrophy.
GRAM, which was recently named to the Inc. 5000 list of fastest growing private companies, supports efforts to accelerate research and raise awareness of Duchenne. Through the sponsorship, GRAM is deepening its community involvement and investment into medical research.
Duchenne is characterized by progressive muscular degeneration and weakness and is the most common fatal genetic disorder diagnosed in childhood. It affects approximately one in every 3,500 live male births (about 20,000 new cases each year worldwide). Young men with Duchenne typically live into their late 20s, and there is currently no cure.
“We are extremely proud to support efforts to raise awareness for this cause. Duchenne affects close to a dozen boys in our community, so this is a cause we strongly believe in,” said Thomas Ross, president and CEO of GRAM. “I’m grateful our organization can contribute to the discovery of a cure.”
About Grand River Aseptic Manufacturing
Grand River Aseptic Manufacturing (GRAM), a parenteral contract manufacturing organization, delivers customized solutions to meet clients’ fill and finish needs from development through commercialization. With capabilities for biologics as well as controlled substances, GRAM’s expert project managers and modern facilities support pharmaceutical development and cGMP manufacturing, analytical testing and regulatory filing. For more information, visit grandriverasepticmfg.com.